NuCana plc (NASDAQ: NCNA)
$3.01
-0.0900 ( -2.90% ) 28.5K
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
Market Data
Open
$3.01
Previous close
$3.10
Volume
28.5K
Market cap
$6.96M
Day range
$3.02 - $3.12
52 week range
$2.53 - $21.53
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 1 | Jun 18, 2024 |
6-k | Quarterly Reports | 4 | May 16, 2024 |
6-k | Quarterly Reports | 28 | May 13, 2024 |
6-k | Quarterly Reports | 2 | May 01, 2024 |
6-k | Quarterly Reports | 2 | Apr 16, 2024 |
6-k | Quarterly Reports | 2 | Apr 09, 2024 |
6-k | Quarterly Reports | 2 | Mar 27, 2024 |
6-k | Quarterly Reports | 2 | Mar 20, 2024 |
20-f | Annual reports | 117 | Mar 20, 2024 |
6-k | Quarterly Reports | 5 | Nov 16, 2023 |